Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, received approval for use with the ultra-rapid-acting insulin ...

Tandem is hoping that the experimental predictive low glucose suspend (PLGS) feature on its t:slim X2 insulin pump will give it the edge. The company has been updating features on its pump over ...

Tandem Diabetes Care TNDM has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly’s ultra-rapid acting insulin, Lyumjev, in the European ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

This impressive performance was largely attributed to the successful launch of the company's Mobi insulin pump system. The Mobi launch has been a significant driver of growth for Tandem ...

RBC Capital Markets initiated coverage on Tandem ... insulin delivery systems. The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years ...

Tandem Diabetes Care reported a strong second quarter in 2024, outperforming expectations in both sales and EBITDA. This impressive performance was largely attributed to the successful launch of the ...